Jamal; Sumayah

Patent Applications and Registrations

Patent applications and USPTO patent grants for Jamal; Sumayah.The latest application filed is for "treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists".

Company Profile

8.9.15

Jamal; Sumayah - New York NY

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Treatment Of Urothelial And Kidney Cancers By Use Of Endothelin B Receptor Antagonists App 20220265628 - Jamal; Sumayah	2022-08-25
Methods And Compositions For Treatment Of Endothelin B Receptor Expressing Tumors App 20220257700 - Jamal; Sumayah	2022-08-18
Methods and compositions for treatment of endothelin B receptor expressing tumors Grant 11,338,014 - Jamal May 24, 2	2022-05-24
Deuterated Compounds, Compositions, And Methods For Treating Cancers Associated With Etbr Activation App 20210309694 - Jamal; Sumayah	2021-10-07
Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation Grant 11,066,442 - Jamal July 20, 2	2021-07-20
Etbr Antagonist Compounds, Compositions, And Uses App 20210077562 - JAMAL; Sumayah	2021-03-18
Methods And Compositions For Treatment Of Endothelin B Receptor Expressing Tumors App 20200316049 - JAMAL; Sumayah	2020-10-08
Nanoparticle Compositions Of Endothelin B Receptor Antagonists App 20200316046 - JAMAL; Sumayah	2020-10-08
Methods Of Inhibiting Endothelin B Receptor Expressing Tumor Metastases App 20200289495 - JAMAL; Sumayah	2020-09-17
Methods And Compositions For Inhibiting Metastases Of An Endothelin B Receptor Expressing Cancer App 20200268829 - JAMAL; Sumayah	2020-08-27
Compositions and methods for treating cancers associated with ETBR activation Grant 10,695,400 - Jamal	2020-06-30
Deuterated Compounds, Compositions, And Methods For Treating Cancers Associated With Etbr Activation App 20190345197 - JAMAL; Sumayah	2019-11-14
Etbr Antagonist Compounds, Compositions, And Uses App 20190314444 - JAMAL; Sumayah	2019-10-17
Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation Grant 10,435,434 - Jamal O	2019-10-08
Deuterated Compounds, Compositions, And Methods For Treating Cancers Associated With Etbr Activation App 20190218251 - JAMAL; Sumayah	2019-07-18
Compositions And Methods For Treating Cancers Associated With Etbr Activation App 20170035836 - Jamal; Sumayah	2017-02-09
Cancer treatment with endothelin receptor antagonists Grant 9,125,897 - Schneider , et al. September 8, 2	2015-09-08
Cancer treatment with endothelin receptor antagonists Grant 8,597,645 - Schneider , et al. December 3, 2	2013-12-03
Cancer Treatment With Endothelin Receptor Antagonists App 20130309253 - Schneider; Robert ; et al.	2013-11-21
Cancer Treatment With Endothelin Receptor Antagonists App 20120148602 - Schneider; Robert J. ; et al.	2012-06-14
Cancer treatment with endothelin receptor antagonists Grant 8,067,000 - Schneider , et al. November 29, 2	2011-11-29
Cancer Treatment With Endothelin Receptor Antagonists App 20100003240 - Schneider; Robert J. ; et al.	2010-01-07
Cancer treatment with endothelin receptor antagonists Grant 7,566,452 - Schneider , et al. July 28, 2	2009-07-28

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.